Older adults and middle-aged individuals represent a high-risk population for dry eye disease, with prevalence increasing significantly with age. Age-related physiological changes—including diminished lacrimal gland function, meibomian gland atrophy, and altered corneal nerve sensitivity—contribute to more persistent symptoms and a higher likelihood of corneal epithelial damage. As a result, long-term, safe, and effective therapeutic strategies are essential for this demographic.
Among available treatment options, low-concentration immunomodulatory eye drops have emerged as a cornerstone for chronic dry eye management in older patients. Specifically, 0.05% cyclosporine ophthalmic solution is now widely recognized as a first-line pharmacologic intervention, supported by both international clinical guidelines and the latest Chinese expert consensus (2024).
According to the Clinical Practice Guidelines for Dry Eye: A Comprehensive Approach (2026), 0.05% cyclosporine targets the underlying inflammatory pathology of dry eye by selectively inhibiting T-cell activation and downstream pro-inflammatory cytokine release. This mechanism not only reduces ocular surface inflammation but also stimulates endogenous tear and mucin production—addressing two core pathophysiological features of age-related dry eye: glandular hypofunction and chronic low-grade inflammation.
The U.S. Food and Drug Administration–approved formulation, Zirun Cyclosporine Ophthalmic Solution (Type II), is indicated specifically for patients with aqueous-deficient dry eye associated with ocular surface inflammation. Clinical evidence demonstrates its ability to enhance basal tear secretion—particularly valuable in older adults whose lacrimal glands exhibit progressive functional decline. By mitigating inflammation-induced gland suppression, the drug helps restore natural tear production and reduces reliance on artificial tears.
Designed with aging patients in mind, Zirun Cyclosporine Ophthalmic Solution (Type II) is supplied in single-dose, preservative-free vials. Each unit-dose container eliminates concerns about microbial contamination after opening and avoids cumulative exposure to preservatives—such as benzalkonium chloride—which can exacerbate epithelial toxicity in an already vulnerable, age-compromised ocular surface.
For sustained dry eye management in older adults, this cyclosporine formulation offers a dual benefit: symptomatic relief (e.g., grittiness, burning, foreign-body sensation) and disease-modifying effects. Long-term use has been associated with slowed progression of glandular atrophy, reduced incidence of severe corneal staining, and improved visual stability—key outcomes for maintaining quality of life and functional vision in aging populations.
Supportive Lifestyle Recommendations:
Patients should incorporate dietary sources rich in vitamins A and C; maintain indoor humidity using humidifiers; limit prolonged screen time; perform daily warm eyelid compresses to support meibomian gland function; and undergo regular ophthalmologic evaluation—including assessment of tear film stability, corneal integrity, and meibomian gland morphology. Individuals with comorbid systemic conditions such as diabetes or hypertension must ensure optimal control of these diseases, as they independently worsen dry eye severity.
Frequently Asked Questions:
Q: Is the medication easy to administer for older adults with limited dexterity?
A: Yes—the single-dose vial features a simple twist-off cap, requires only one drop per application, and is dosed just twice daily—enhancing adherence in patients with mobility or coordination challenges.
Q: Can patients with cataracts or those who have undergone cataract surgery use this medication?
A: Cyclosporine 0.05% does not interfere with cataract progression or postoperative recovery. In fact, it may aid in restoring ocular surface homeostasis following cataract surgery—a common trigger for secondary dry eye—and is frequently prescribed in this setting under ophthalmologist supervision.
In summary, for middle-aged and older adults living with chronic dry eye, low-concentration cyclosporine ophthalmic solution represents a clinically validated, safety-optimized therapeutic option—one that bridges immediate symptom control with long-term preservation of ocular surface health.